

Methods

Generation of cyclophilin D-deficient mice

A genomic clone (pKOS 63) containing the CypD locus was isolated from a 129/J mouse genomic library. Lex-1 embryonic stem (ES) cells (derived from the 129SvEvBrd strain) were electroporated with the targeting vector and selected by G418. ES clones with the targeted CypD allele were screened by polymerase chain reaction (PCR) and Southern blotting analysis. Heterozygous mutant ES cells were injected into C57BL/6J blastocysts. Germline transmission of mutant alleles to F₁ offspring was confirmed by PCR and Southern blotting, and F₂ offspring from heterozygous intercrosses were genotyped by PCR and Southern blotting.

Genotyping by PCR

The CypD locus was genotyped by PCR. The wild-type allele (553 base pairs, bp) was detected using a forward primer (5'-GCAGATCAAGCTCCCGACTG-3') and a reverse primer (5'-ACTTGGGAAGCCGAGGTG-3'). To detect the mutant allele (206 bp), a neomycin-specific reverse primer (5'-GCAGCGCATCGCCTTCTATC-3') was used in combination with the wild-type reverse primer described above.

Antibodies

Anti-mouse CypD antibody was produced using a peptide (amino acids 43–57) of CypD. Anti-cytochrome c, anti-cyclophilin A and anti-GAPDH antibodies were purchased from Pharmingen, UpState and Biogenesis, respectively.

Mitochondrial biochemical parameters

Mitochondria were isolated from mouse livers as described previously²⁴. In all experiments, except for assessment of respiration, mitochondria were in medium containing 0.3 mM mannitol, 10 mM potassium HEPES (pH 7.4), 0.1% fatty acid-free BSA, 300 μM potassium phosphate (pH 7.4) and 4.2 mM succinate.

Mitochondrial PPIase activity was measured as described previously²⁵, except that the final concentration of the synthetic peptide substrate (succinyl-Ala-Ala-Pro-Phe-4-nitroanilide) was 75 μM. The activity was expressed as K/K_0 , where K and K_0 are the first-order rate constants in the presence and absence of the mitochondrial lysate, respectively. The mitochondrial membrane potential ($\Delta\psi$) was assessed by measuring the $\Delta\psi$ -dependent uptake of rhodamine 123 (Rh123, ref. 24). Mitochondrial swelling was monitored by the decrease of 90° light scatter at 520 nm, which was determined using a spectrophotometer (Hitachi F-4500). Mitochondrial respiration was measured with an O₂ electrode (Rank Brothers) in respiration buffer²⁴. The external mitochondrial Ca²⁺ concentration was monitored using a Ca²⁺-specific electrode (Orion). The amount of intra-mitochondrial Ca²⁺ was measured using ⁴⁵Ca²⁺. Isolated mitochondria were incubated with ⁴⁵Ca²⁺ for 25 min, and then the mitochondria (1 mg protein) were centrifuged at 12,000g for 3 min. The pellet and supernatant fractions were collected and their radioactivity measured using a liquid scintillation counter (Wallac 1409). Cytochrome c release was determined as previously described¹².

In anoxia/reoxygenation experiments, mitochondria were suspended in a tube and treated with 100% N₂ gas. The gas-saturated tube was sealed with parafilm and left for 30 min, and the mitochondria were then reoxygenated by shaking in a 12-well plate at room temperature for 30 min.

Cell death assay

Primary cultures of MEFs were obtained from CypD-deficient and control littermate embryos at embryonic day 14.5. MEFs immortalized by SV40 T antigen were also used. Hepatocytes were isolated from CypD-deficient mice and their control littermates at 3–4 months of age using the retrograde two-step collagenase perfusion technique²⁶. Cell viability was assessed by propidium iodide (PI) staining, Annexin-V staining or the cell titer blue (CTB) assay. Briefly, cells were stained with 1 μM PI or 1 μM Cy3-conjugated Annexin-V for 5 min at room temperature and were analysed using a flow cytometer (Becton-Dickinson). The CTB assay, which measures the metabolic activity of viable cells, was carried out using Cell Titer Blue reagent (Promega). The nuclear morphology was observed with 10 μM Hoechst 33342 and 1 μM PI staining as described previously²⁷. DEVDase activity (cleavage of the caspase-3 substrate DEVD-amc) was measured as described elsewhere²⁸.

Laser scanning confocal microscopy

Hepatocytes were cultured in covered glass-bottomed 24-well dishes coated with type I collagen (Iwaki glass) for 16–20 h. To monitor mitochondrial $\Delta\psi$, hepatocytes were loaded with 0.25 μM TMRM (Molecular Probes) as described previously²⁹. To monitor the mitochondrial Ca²⁺ level, hepatocytes were loaded with 5 μM Rhod2-AM (Molecular Probes) in culture medium containing 0.05% Pluronic F-127 (Molecular Probes) and 0.1 mM sulphydrylase for 2 h at 4 °C for mitochondria-selective loading as described previously¹⁶.

Ischaemia/reperfusion experiments

Using CypD-deficient and wild-type littermate mice at 10–12 weeks of age, ischaemia/reperfusion of the heart was performed as described previously³⁰. Briefly, under general anaesthesia with mechanical ventilation, a silk thread (7-0) was passed around the left coronary artery (LCA) about 1 mm distal to the LCA origin to make a snare. After 30 min ligation of the LCA, the snare was released for 2 h. The infarct size was evaluated by double staining using Evans blue dye and triphenyltetrazolium chloride (TTC). The area at risk

was defined as the ratio of the area of the ischaemic region to the left ventricular area, and the infarct size was defined as the ratio of the area of the infarct region to that of the ischaemic region.

Statistical evaluation

Statistical evaluation was performed by unpaired *t*-tests. Data are presented as mean ± s.e.m. or mean ± s.d.

Received 2 September 2004; accepted 4 January 2005; doi:10.1038/nature03317.

1. Tsujimoto, Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. *J. Cell. Physiol.* **195**, 158–167 (2003).
2. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. *Science* **305**, 626–629 (2004).
3. Halestrap, A. P., McStay, G. P. & Clarke, S. J. The permeability transition pore complex: another view. *Biochimie* **84**, 153–166 (2002).
4. Crompton, M. On the involvement of mitochondrial intermembrane junctional complexes in apoptosis. *Curr. Med. Chem.* **10**, 1473–1484 (2003).
5. Kokoszka, J. E. *et al.* The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. *Nature* **427**, 461–465 (2004).
6. Halestrap, A. P. Mitochondrial permeability: dual role for the ADP/ATP translocator? *Nature* [online] **430**, 983 (2004) (doi:10.1038/nature02816).
7. Galat, A. & Metcalfe, S. M. Peptidylproline cis/trans isomerases. *Prog. Biophys. Mol. Biol.* **63**, 67–118 (1995).
8. Broekemeier, K. M., Dempsey, M. E. & Pfeiffer, D. R. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. *J. Biol. Chem.* **264**, 7826–7830 (1989).
9. He, L. & Lemasters, J. J. Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function? *FEBS Lett.* **512**, 1–7 (2002).
10. Scorrano, L. *et al.* A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. *Dev. Cell* **2**, 55–67 (2002).
11. Wei, M. C. *et al.* Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* **292**, 727–730 (2001).
12. Narita, M. *et al.* Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. *Proc. Natl. Acad. Sci. USA* **95**, 14681–14686 (1998).
13. Eskes, R. *et al.* Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg²⁺ ions. *J. Cell Biol.* **143**, 217–224 (1998).
14. Finucane, D. M., Bossy-Wetzell, E., Waterhouse, N. J., Cotter, T. G. & Green, D. R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. *J. Biol. Chem.* **274**, 2225–2233 (1999).
15. von Ahnen, O. *et al.* Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. *J. Cell Biol.* **150**, 1027–1036 (2000).
16. Trollinger, D. R., Cascio, W. E. & Lemasters, J. J. Selective loading of Rhod 2 into mitochondria shows mitochondrial Ca²⁺ transients during the contractile cycle in adult rabbit cardiac myocytes. *Biochem. Biophys. Res. Commun.* **236**, 738–742 (1997).
17. Weiss, J. N., Korge, P., Honda, H. M. & Ping, P. Role of the mitochondrial permeability transition in myocardial disease. *Circ. Res.* **93**, 292–301 (2003).
18. Shimizu, S. *et al.* Beneficial effects of cyclosporine on reoxygenation injury in hypoxic rat liver. *Transplantation* **57**, 1562–1566 (1994).
19. Javadov, S. A. *et al.* Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. *J. Physiol. (Lond.)* **549**, 513–524 (2003).
20. Matsumoto, S., Friberg, H., Ferrand-Drake, M. & Wieloch, T. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. *J. Cereb. Blood Flow Metab.* **19**, 736–741 (1999).
21. Khaspekov, L., Friberg, H., Halestrap, A., Viktorov, I. & Wieloch, T. Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose/oxygen deprivation-induced damage to rat cultured hippocampal neurons. *Eur. J. Neurosci.* **11**, 3194–3198 (1999).
22. Zamzami, N. & Kroemer, G. The mitochondrion in apoptosis: how Pandora's box opens. *Nature Rev. Mol. Cell Biol.* **2**, 67–71 (2001).
23. Li, Y., Johnson, N., Capano, M., Edwards, M. & Crompton, M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. *Biochem. J.* **383**, 101–109 (2004).
24. Shimizu, S. *et al.* Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. *Proc. Natl. Acad. Sci. USA* **95**, 1455–1459 (1998).
25. Fischer, G., Wittmann-Liebold, B., Lang, K., Kieffhaber, T. & Schmid, F. X. Cyclophilin and peptidyl-prolyl *cis-trans* isomerase are probably identical proteins. *Nature* **337**, 476–478 (1989).
26. Hatano, E. *et al.* The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. *J. Biol. Chem.* **275**, 11814–11823 (2000).
27. Shinzawa, K. & Tsujimoto, Y. PLA2 activity is required for nuclear shrinkage in caspase-independent cell death. *J. Cell Biol.* **163**, 1219–1230 (2003).
28. Shimizu, S., Eguchi, Y., Kamiie, W., Matsuda, H. & Tsujimoto, Y. Bcl-2 expression prevents activation of the ICE protease cascade. *Oncogene* **12**, 2251–2257 (1996).
29. Byrne, A. M., Lemasters, J. J. & Nieminen, A. L. Contribution of increased mitochondrial free Ca²⁺ to the mitochondrial permeability transition induced by tert-butylhydroperoxide in rat hepatocytes. *Hepatology* **29**, 1523–1531 (1999).
30. Yamashita, N. *et al.* Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. *J. Exp. Med.* **189**, 1699–1706 (1999).

Supplementary Information accompanies the paper on www.nature.com/nature.

Acknowledgements We are grateful to K. Tagawa for helpful discussion and C. Thompson for providing Bak-deficient mice. CypD-deficient mice were developed in collaboration with Lexicon Genetics Incorporated. This study was supported in part by a grant for Scientific Research on

Priority Areas, a grant for Center of Excellence Research, a grant for the 21st century COE Program, a grant for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan, and by a grant for Research on Dementia and Fracture from the Ministry of Health, Labour and Welfare of Japan.

Competing interests statement The authors declare that they have no competing financial interests.

Correspondence and requests for materials should be addressed to Y.T. (tsujimot@gene.med.osaka-u.ac.jp).

Nuclear Translocation of Caspase-3 Is Dependent on Its Proteolytic Activation and Recognition of a Substrate-like Protein(s)*[§]

Received for publication, November 19, 2004
Published, JBC Papers in Press, November 29, 2004,
DOI 10.1074/jbc.C400538200

Shinji Kamada^{§¶}, Ushio Kikkawa[§],
Yoshihide Tsujimoto[¶], and Tony Hunter^{‡**}

From the [‡]Molecular and Cell Biology Laboratory, The Salk Institute, La Jolla, California 92037, the [§]Biosignal Research Center, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo 657-8501, Japan, and the [¶]Laboratory of Molecular Genetics, Department of Post-Genomics and Diseases, Osaka University Medical School and Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Caspase-3 is thought to play an important role(s) in the nuclear morphological changes that occur in apoptotic cells and many nuclear substrates for caspase-3 have been identified despite the cytoplasmic localization of procaspase-3. Therefore, whether activated caspase-3 is localized in the nuclei and how active caspase-3 has access to its nuclear targets are important and unresolved questions. Here we confirmed nuclear localizations for both caspase-3-p17 and caspase-3-p12 subunits of active caspase in apoptotic cells using subcellular fractionation analysis. We also prepared polyclonal and monoclonal antibodies specific for active caspase-3 to define the subcellular localization of active caspase-3. Immunocytochemical observations using anti-active caspase-3 antibodies showed nuclear accumulation of active caspase-3 during apoptosis. In addition, caspase-3, but not caspase-7, translocated from the cytoplasm into the nucleus after induction of apoptosis. Mutations at the cleavage site between the p17 and p12 subunits and the substrate recognition site for the P3 amino acid of the DXXD substrate cleavage motif inhibited nuclear translocation of caspase-3, indicating that nuclear transport of active caspase-3 required proteolytic activation and substrate recognition. These results suggest that active caspase-3 is translocated in association with a substrate-like protein(s) from the cytoplasm into the nucleus during progression through apoptosis.

Apoptosis is a fundamental cellular process involved in many biological phenomena, including morphogenesis and maintenance of tissue homeostasis. Apoptosis is morphologically characterized by a dramatic execution phase that includes loss of cell volume, plasma membrane blebbing, and chromatin condensation followed by packaging of the cellular contents into membrane-enclosed vesicles called apoptotic bodies. These changes reflect complex biochemical events carried out by a family of cysteine proteases called caspases (1). Caspases are divided into initiator caspases with long prodomains (caspase-8, -9, and -10) and effector caspases with short prodomains (caspase-3, -6, and -7). Initiator caspases activate effector caspases, which in turn cleave intracellular substrates, resulting in the dramatic morphological and biochemical changes characteristic of apoptosis (2–4).

Caspase-3 has been implicated as a key mediator of apoptosis in mammalian cells and is synthesized as a latent proenzyme composed of 277 amino acids (5–9). In response to various death signals, the caspase-3 proenzyme is cleaved by initiator caspases at Asp²⁸ and Asp¹⁷⁵ to generate the active large (p17) and small (p12) subunits, forming an active heterotetramer. Although the precursor form of caspase-3 is localized in the cytoplasm, caspase-3 plays essential roles in the nuclear changes in apoptotic cells (9, 10). These results suggested that some cytoplasmic substrates translocate into the nucleus after cleavage by caspase-3 leading to nuclear morphological changes. In this scenario, caspase-activated DNase (CAD)^{1/} DNA fragmentation factor (DFF) 40 and apoptotic chromatin condensation inducer in the nucleus (Acinus) were identified in the cytoplasmic fraction of apoptotic cells (11–13). However, CAD/DFF40 and Acinus were suggested to be localized in the nucleus even before apoptosis induction (12–14). Furthermore, many substrates for caspase-3 have been identified in the nucleus (2–4, 15). Therefore, caspase-3 seems to translocate from the cytoplasm into the nucleus after apoptosis induction, and it was proposed that active caspase-3 is translocated into nuclei by simple diffusion after disruption of nuclear-cytoplasmic barrier (16). However, the precise molecular mechanism of nuclear translocation of active caspase-3 is still unknown.

In the present study, we have demonstrated the nuclear localization of active caspase-3 in apoptotic cells by using antibodies specific for the large and small subunits of active caspase-3. Furthermore, we have shown that the nuclear translocation of active caspase-3 required proteolytic activation and substrate recognition by using caspase-3 mutants, suggesting that the nuclear translocation of active caspase-3 is not mediated by simple diffusion but is operated by an active transport system.

EXPERIMENTAL PROCEDURES

Cell Culture and Apoptosis Induction—HepG2 cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS). For induction of apoptosis, HepG2 cells were treated with 1 μ g/ml of an agonistic anti-Fas antibody (CH-11; Kamiya Biomedical Co.) in the presence of 0.2 μ g/ml actinomycin D or with 200 μ g/ml etoposide. Transfection was performed using GenePORTER 2 (Gene Therapy Systems) according to the manufacturer's instructions.

¹The abbreviations used are: CAD, caspase-activated DNase; DFF, DNA fragmentation factor; GFP, green fluorescent protein; TXRD, Texas Red; PBS, phosphate-buffered saline; pAb, polyclonal antibody; PKC, protein kinase C; NPC, nuclear pore complex.

* This work was supported in part by grants-in-aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, and Culture of Japan (to S. K.) and by Public Health Service Grants CA82863 and CA14195 from the NCI (to T. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[§]The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Experimental Procedures, Results, and Fig. S1.

[¶]To whom correspondence may be addressed. Tel.: 81-78-803-5965; Fax: 81-78-803-5972; E-mail: skamada@kobe-u.ac.jp.

** Frank and Else Schilling American Cancer Society Professor. To whom correspondence may be addressed: Molecular and Cell Biology Laboratory, The Salk Inst., 10010 North Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-453-4100; Fax: 858-457-4765; E-mail: hunter@salk.edu.

Subcellular Fractionation—For preparation of digitonin-lysed cell fractions, cells were washed with PBS and suspended in PBS followed by lysis with 0.3 mg/ml digitonin for 3 min at 37 °C and centrifuged at 12,000 × *g* for 5 min at 4 °C. The pellet and supernatant fractions were used for immunoblot analysis with the pellet fraction including nuclei and heavy membranes and the supernatant fraction containing cytoplasm and light membranes.

For preparation of subcellular fractions, cells were washed with PBS and suspended in hypotonic solution (10 mM Hepes (pH 7.4), 10 mM MgCl₂, 42 mM KCl, 10 μM lactacystin) for 5 min on ice. Cells were lysed using a Dounce homogenizer and centrifuged at 600 × *g* for 10 min to collect crude nuclei that were further purified as described below. The supernatant was further centrifuged at 100,000 × *g* for 90 min. The pellet and supernatant were used as membrane and cytoplasmic fractions, respectively. The crude nuclear fraction was passed through a 27-gauge needle several times, extensively washed with hypotonic solution, and centrifuged through a 2 M sucrose cushion at 150,000 × *g* for 60 min. The pellet was used as a purified nuclear fraction. Nonidet P-40-treated nuclei were prepared by washing the purified nuclei with hypotonic solution containing 0.5% Nonidet P-40 to remove contaminating membranes.

Antibodies—Anti-active caspase-3 polyclonal (2622) and monoclonal (CS-1) antibodies, which recognize caspase-3-p12, were generated (see supplemental material). Anti-caspase-3 monoclonal antibody (C31720) was obtained from Transduction Laboratories; anti-caspase-3 polyclonal antibodies (sc-1224), anti-PKC δ polyclonal antibodies (sc-937), and anti-lamin B1 polyclonal antibodies (sc-6217) were from Santa Cruz Biotechnology; anti-active caspase-3 pAb (G7481) was from Promega; anti-green fluorescent protein (GFP) monoclonal antibody (8371) from Clontech; and anti-caspase-3 polyclonal antibodies (9662) was from Cell Signaling Technology.

Fluorescence Microscopy—For immunofluorescence analysis, cells were fixed with 3.7% formaldehyde in PBS for 10 min, washed with PBS twice, permeabilized in 0.5% Triton X-100 in PBS for 10 min, and washed with PBS twice. Cells were then incubated with primary antibodies in PBS containing 1% BSA overnight at 4 °C. After washing with PBS twice, cells were incubated with Texas red (TXRD)-, fluorescein isothiocyanate-, Alexa Fluor 488-, or Cy3-labeled secondary antibodies for 10 min at room temperature and washed with PBS twice. After staining nuclei with 10 μM Hoechst 33342 (Calbiochem), cells were examined under a fluorescence microscope (Leitz Laborlux) or a confocal laser scanning microscope (Carl Zeiss).

Plasmid Constructions—The wild type procaspase-3 cDNA fragment was cloned into the EcoRI site of pUC-CAGGS (17) to generate pCAG-casp3. To construct expression plasmids for caspase fused to the N terminus of GFP, PCR was carried out using caspase-3 and caspase-7 cDNAs as templates. The fragments encoding caspase-3 or caspase-7 were cloned into the EcoRI-BamHI site of pEGFP-N1 (Clontech) to generate pcasp3-Wt-GFP or pcasp7-Wt-GFP. To generate C163S, D175A, R64E, and R207E mutations, a PCR method employing mutagenic oligonucleotide primers was used. Caspase-3 cDNAs containing these mutations were cloned into the EcoRI-BamHI site of pEGFP-N1 to generate pcasp3-C163S-GFP, pcasp3-D175A-GFP, pcasp3-R64E-GFP, and pcasp3-R207E-GFP.

RESULTS AND DISCUSSION

Although it has been widely accepted that procaspase-3 is cleaved to generate the active form in the cytoplasm, the enzymatic activity of caspase-3-like proteases can be found in the nuclear fraction of apoptotic cells (18–20). It is, however, necessary to determine whether activated caspase-3 itself is present in the nuclei of apoptotic cells, as opposed to other caspases such as caspase-7 and -8 that can also cleave caspase-3 substrates (21, 22). The p17 subunit of active caspase-3 is detected not only in the cytoplasmic and mitochondrial fractions but also in the nuclear fraction of apoptotic cells (23). However, the localization of the p12 subunit of active caspase-3 remained to be determined, which is important, because caspase-3 enzymatic activity requires both p17 and p12 subunits. Therefore, we initially investigated the localization of the caspase-3-p12 subunit. HepG2 cells treated with or without an agonistic anti-Fas antibody were separated into pellet and supernatant fractions after lysis with digitonin, followed by immunoblotting (Fig. 1A). Although procaspase-3 was present in the supernatant fraction irrespective of induction of apoptosis, the caspase-




Fig. 1. Nuclear localization of caspase-3-p17 and caspase-3-p12 subunits in apoptotic HepG2 cells. *A*, detection of caspase-3-p12 subunit in HepG2 cells. HepG2 cells were treated with or without the anti-Fas antibody in the presence of actinomycin D for 12 h, and pellet (*P*) and supernatant (*S*) fractions were prepared after lysis with digitonin. Each fraction was subjected to SDS-PAGE and immunoblotted with anti-caspase-3 polyclonal antibodies (sc-1224 from Santa Cruz Biotechnology), which detect both procaspase-3 and caspase-3-p12. *B*, subcellular fractionation of normal (*left panel*) and apoptotic (*right panel*) HepG2 cells. Subcellular fractions from apoptotic HepG2 cells were prepared after transfection with pCAG-casp3 followed by incubation for 24 h and treatment with the anti-Fas antibody in the presence of actinomycin D for 12 h. Subcellular fractions, standardized to represent equal numbers of cells in each fraction, were subjected to SDS-PAGE and immunoblotted with anti-caspase-3 monoclonal antibody (C31720 from Transduction Laboratories), anti-caspase-3 antibody (9662 from Cell Signaling Technology), anti-caspase-3 polyclonal antibodies (sc-1224 from Santa Cruz Biotechnology), anti-PKC δ polyclonal antibodies, or anti-lamin B1 polyclonal antibodies. *T*, total cell lysate; *C*, cytoplasmic fraction; *M*, membrane fraction; *N*, purified nuclear fraction; *N*⁺, purified nuclear fraction after treatment with 0.5% Nonidet P-40.

3-p12 subunit was present in both the pellet fraction (including nuclei) and the supernatant fraction after induction of apoptosis. Subcellular fractionation was used to confirm the nuclear localization of active caspase-3 in apoptotic cells. Since active caspase-3 may be degraded by the ubiquitin-proteasome pathway (24–26), procaspase-3 was transiently overexpressed to elevate the expression levels of caspase-3, and the preparation of subcellular fractions was carried out in the presence of a proteasome inhibitor, lactacystin; PKC δ and lamin B1 were used as cytoplasmic and nuclear fraction markers, respectively. Normal non-transfected HepG2 cells (Fig. 1*B*, *left panel*) or transfected HepG2 cells treated with the anti-Fas antibody for 12 h (Fig. 1*B*, *right panel*) were fractionated into nuclear, membrane, and cytoplasmic fractions. Although the expression level of procaspase-3 in transfected cells was more than five times higher than in non-transfected cells, the cytoplasmic localization of procaspase-3 was unaffected by overexpression. Both caspase-3-p17 and caspase-3-p12 were detected not only in the cytoplasmic fraction but also in the nuclear fraction even after treatment with 0.5% Nonidet P-40 (Fig. 1*B*, *right panel*). These results strongly suggested that active caspase-3 was present in the nuclei of apoptotic cells.

To directly assess the localization of active caspase-3, we prepared antibodies specific for active caspase-3-p12 subunit. Since procaspase-3 is processed at Asp²⁸ and Asp¹⁷⁵ sites to generate new N and C termini, we generated four affinity-purified polyclonal and three monoclonal antibodies that specifically recognize the newly exposed N-terminal region of caspase-3-p12 (see supplemental material). We also used the commercially available anti-active caspase-3 specific antibodies (G7481, Promega) that recognize the newly exposed C terminus of caspase-3-p17. Al-




FIG. 2. Nuclear accumulation of active caspase-3 in apoptotic cells. A, cytoplasmic localization of procaspase-3 in normal cells. After fixation and permeabilization, HepG2 cells were incubated with anti-caspase-3 polyclonal antibodies (sc-1224 from Santa Cruz Biotechnology) and TXRD-labeled secondary antibodies (panel a), followed by staining the nuclei with Hoechst 33342 (panel b). Photographs were taken of the same fields in panels a and b, and merged images of TXRD and Hoechst staining are shown in panel c. B, accumulation of active caspase-3 around the apoptotic nuclei. HepG2 cells were treated with the anti-Fas antibody in the presence of actinomycin D (act D) for 12 h (panels a-c, g-i, and m-o) or with etoposide for 40 h (panels d-f, j-l, and p-r). After fixation and permeabilization, the cells were incubated with anti-active caspase-3 polyclonal antibodies (2622) (panels a and d), anti-active caspase-3 monoclonal antibody (CS-1) (panels g and j), anti-active caspase-3 pAb (G7481 from Promega) (panels m and p), and TXRD-labeled secondary antibodies (panels a, d, g, j, m, and p), followed by staining the nuclei with Hoechst 33342 (panels b, e, h, k, n, and q). Photographs were taken of the same fields in panels a-c, d-f, g-i, j-l, m-o, and p-r, and merged images of TXRD and Hoechst staining are shown in panels c, f, i, l, o, and r,




FIG. 3. Nuclear translocation of active caspase-3 requires proteolytic activation and substrate recognition, but not catalytic activity. A, localization of caspase-3- and caspase-7-GFP fusion proteins in HepG2 cells. One day before transfection, HepG2 cells were seeded at a density of 2×10^5 cells per well in 6-well dishes. In each well, 2 μ g of plasmids expressing caspase-GFP fusion proteins were transfected and incubated for 24 h. After treatment with or without the anti-Fas antibody in the presence of actinomycin D (act D) for 12 h, cells were fractionated after lysis with digitonin and subjected to SDS-PAGE and immunoblotted with anti-GFP monoclonal antibody. S, supernatant fraction; P, pellet fraction. B, nuclear localization of caspase-3-, but not caspase-7-, GFP fusion protein in apoptotic cells with confocal laser scanning microscopy. One day before transfection, HepG2 cells were seeded at a density of 2×10^5 cells per 35-mm glass bottom dish. In each dish, 2 μ g of pcasp3-Wt-GFP (panels a-i) or pcasp7-Wt-GFP (panels j-r) plasmids were transfected and incubated for 24 h. After treatment without (panels a-c and j-l) or with the anti-Fas antibody in the presence of actinomycin D (act D) for 12 h (panels d-f and m-o) or with etoposide for 40 h (panels g-i and p-r), GFP expression (panels a, d, g, j, m, and p) was observed with confocal laser scanning microscope after staining with Hoechst 33342 (panels b, e, h, k, n, and q). Photographs were taken of the same fields in panels a-c, d-f, g-i, j-l, m-o, and p-r, and merged images of GFP and Hoechst staining are shown in panels c, f, i, l, o, and r, respectively. Bar, 10 μ m.

though procaspase-3 was detected in the cytoplasm of untreated normal cells (Fig. 2A), in most apoptotic cells stained with anti-active caspase-3 antibodies, which recognize the newly exposed N terminus of caspase-3-p12 (Fig. 2B, panels a-l) or the newly exposed C terminus of caspase-3-p17 (Fig. 2B, panels m-r), the signal was strongest around the condensed nucleus. To deter-

minally, C, detection of active caspase-3 in apoptotic nuclei. HepG2 cells were treated with the anti-Fas antibody in the presence of actinomycin D (act D) for 12 h or with etoposide for 40 h. After fixation and permeabilization, the cells were incubated with anti-active caspase-3 pAb (G7481 from Promega) and anti-lamin B1 polyclonal antibodies as a nuclear envelope marker, and Cy3- and Alexa Fluor 488-labeled secondary antibodies, followed by staining the nuclei with Hoechst 33342, and observed with confocal laser scanning microscope. The z-series of images from five sections are shown. Bars, 10 μ m.

mine whether active caspase-3 is actually present in the nucleus, apoptotic cells were stained with the anti-active caspase-3 antibodies and antibodies against lamin B1, a nuclear envelope marker, and analyzed by confocal laser scanning microscopy (Fig. 2C). The signal for active caspase-3 was detected both in and around the condensed nuclei. Taken together, these results indicate that active caspase-3 is present not only in the cytoplasm but also in the nuclei of apoptotic cells.

To examine the molecular mechanisms governing translocation of caspase-3 from the cytoplasm into the nucleus, we constructed various procaspase-3 mutants fused with GFP. These constructs were transiently transfected into HepG2 cells. After treatment with or without the agonistic anti-Fas antibody to induce apoptosis, supernatant and pellet fractions were prepared after digitonin lysis and immunoblotted with the anti-GFP antibody (Fig. 3A). Although casp3-Wt-GFP was predominantly present in supernatant, like the unprocessed form before Fas treatment, proteolytically activated casp3-p12-GFP was recovered in both the supernatant and pellet fractions after Fas treatment (Fig. 3A). In contrast, caspase-7, another effector caspase, did not translocate to the nucleus, with both casp7-Wt-GFP and casp7-p12-GFP being detected only in the supernatant fraction irrespective of Fas treatment. Consistently, confocal laser scanning microscopy indicated that casp3-Wt-GFP was present in both cytoplasm and nuclei, whereas casp7-Wt-GFP was found only in the cytoplasm in apoptotic cells (Fig. 3B). These results suggested that the nuclear translocation of effector caspases is specific for caspase-3 and that the nuclear translocation of caspase-3 is an active process and not simply entail diffusion after disruption of the nuclear-cytoplasmic barrier.

To determine whether caspase-3 activation is needed for nuclear translocation, we constructed procaspase-3 mutants that cannot be activated, recognize substrates, or cleave substrates, respectively. Casp3-D175A-GFP, which is not activated due to mutation of the cleavage site between the p17 and p12 subunits, did not translocate after anti-Fas treatment, suggesting that the proteolytic activation of caspase-3 is necessary for its nuclear translocation (Fig. 3A). The three-dimensional structure of caspase-3 (27, 28) shows that Arg⁶⁴ and Arg²⁰⁷ are essential for recognition of the P1 and P3 amino acids of the DXDX cleavage motif substrates, respectively. Cell fractionation analysis showed that casp3-R64E-GFP, but not casp3-R207E-GFP, translocated from cytoplasm to nuclei after Fas treatment, indicating that recognition of P3, but not P1, of a substrate(s) is necessary for nuclear translocation of active caspase-3 (Fig. 3A). Furthermore, casp3-C163S-GFP, in which the catalytic Cys is mutated, translocated from the cytoplasm into nuclei, indicating that substrate cleavage by caspase-3 is not essential for the translocation of active caspase-3. These results suggested that proteolytic activation and substrate recognition, but not substrate cleavage, are necessary for the nuclear translocation of active caspase-3.

Nuclear pore complexes (NPCs) mediate bidirectional transport between the cytoplasm and the nucleus (29). The NPC constitutes a passive diffusion channel, which allows the diffusion of ions, metabolites, and small proteins whose relative molecular mass is less than about 40 kDa. Proteins above the size limit can enter the nucleus by energy-dependent mechanisms. Caspase-3 lacks a typical consensus nuclear localization signal, and the active caspase-3 tetramer is too big to enter the nucleus passively. Recently, Faleiro and Lazebnik (16) reported that caspase-9 inactivates nuclear transport and increases the diffusion limit of the nuclear pore, leading to the entrance of caspase-3 into nuclei by diffusion. If caspase-3 enters the nucleus by simple diffusion, procaspase-3 as well as active caspase-3 and other caspases including caspase-7 would also be

detected in the nuclear fraction of apoptotic cells. However, our data showed that neither procaspase-3 nor caspase-7 translocated into nuclei after apoptosis induction. Furthermore, active nuclear transport is required for the nuclear morphological changes induced by various apoptotic stimuli (30), and nuclear translocation of active caspase-3 required proteolytic activation and recognition of substrate-like protein(s). Therefore, we propose that the nuclear translocation of active caspase-3 is dependent on active nuclear transport. Identification of the substrate-like protein(s) which function as a carrier protein to transport active caspase-3 from the cytoplasm into nucleus in apoptotic cells is needed to clear the molecular mechanisms of nuclear translocation of active caspase-3.

Acknowledgments—We thank Drs. Yoshiteru Kobayashi and Shinji Tanahashi (Wako Pure Chemical Industries, Osaka, Japan) for cooperation in generating antibodies, Dr. Jeong-Hwa Lee for technical support in immunofluorescence analysis, Drs. Joel D. Levenson and Han-Kuei Huang for critical reading of the manuscript, Dr. Vishva M. Dixit for the pcDNA3/Yama plasmid, and Dr. Jun-ichi Miyazaki for the pUC-CAGGS plasmid.

REFERENCES

- Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996) *Cell* **87**, 171
- Cryns, V., and Yuan, J. (1998) *Genes Dev.* **12**, 1551–1570
- Thornberry, N. A., and Lazebnik, Y. (1998) *Science* **281**, 1312–1316
- Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) *Annu. Rev. Biochem.* **68**, 383–424
- Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1994) *J. Biol. Chem.* **269**, 30761–30764
- Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) *Cell* **81**, 801–809
- Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffon, P. R., Labelle, M., Lazebnik, Y. A., Mungay, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, Y. L., and Miller, D. K. (1995) *Nature* **376**, 37–43
- Kuida, K., Zheng, T. S., Na, S., Kuan, C., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R. A. (1996) *Nature* **384**, 368–372
- Woo, M., Hakem, R., Soengas, M. S., Duncan, G. S., Shahinian, A., Kagi, D., Hakem, A., McCurrach, M., Khoo, W., Kaufman, S. A., Senaldi, G., Howard, T., Lowe, S. W., and Mak, T. W. (1998) *Genes Dev.* **12**, 806–819
- Zheng, T. S., Schlosser, S. F., Dao, T., Hingorani, R., Crispe, I. N., Boyer, J. L., and Flavell, R. A. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 13618–13623
- Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) *Nature* **391**, 43–50
- Liu, X., Li, P., Widlak, P., Zou, H., Luo, X., Garrard, W. T., and Wang, X. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 8461–8466
- Sahara, S., Aoto, M., Eguchi, Y., Imamoto, N., Yoneda, Y., and Tsujimoto, Y. (1999) *Nature* **401**, 168–173
- Lechardeur, D., Drzymala, L., Sharma, M., Zylka, D., Kinach, R., Pacia, J., Hicks, C., Usmani, N., Rommens, J. M., and Lukacs, G. L. (2000) *J. Cell Biol.* **150**, 321–334
- Fischer, U., Janicke, R. U., and Schulze-Osthoff, K. (2003) *Cell Death Differ.* **10**, 76–100
- Faleiro, L., and Lazebnik, Y. (2000) *J. Cell Biol.* **151**, 951–959
- Niwa, H., Yamamura, K., and Miyazaki, J. (1991) *Gene (Amst.)* **108**, 193–199
- Martins, L. M., Mesner, P. W., Kottke, T. J., Basi, G. S., Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. (1997) *Blood* **90**, 4283–4296
- Mandal, M., Adam, L., and Kumar, R. (1999) *Biochem. Biophys. Res. Commun.* **260**, 775–780
- Takemoto, K., Nagai, T., Miyawaki, A., and Miura, M. (2003) *J. Cell Biol.* **160**, 235–243
- Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. (1997) *J. Biol. Chem.* **272**, 17907–17911
- Garcia-Calvo, M., Peterson, E. P., Leitinger, B., Ruel, R., Nicholson, D. W., and Thornberry, N. A. (1998) *J. Biol. Chem.* **273**, 32608–32613
- Zhivotovskiy, B., Samali, A., Gahm, A., and Orrenius, S. (1999) *Cell Death Differ.* **6**, 644–651
- Huang, H., Joazeiro, C. A., Bonfoco, E., Kamada, S., Levenson, J. D., and Hunter, T. (2000) *J. Biol. Chem.* **275**, 26661–26664
- Suzuki, Y., Nakabayashi, Y., and Takahashi, R. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 8662–8667
- Chen, L., Smith, L., Wang, Z., and Smith, J. B. (2003) *Mol. Pharmacol.* **64**, 334–345
- Rotonda, J., Nicholson, D. W., Fazil, K. M., Gallant, M., Gareau, Y., Labelle, M., Peterson, E. P., Rasper, D. M., Ruel, R., Vaillancourt, J. P., Thornberry, N. A., and Becker, J. W. (1996) *Nat. Struct. Biol.* **3**, 619–625
- Wei, Y., Fox, T., Chambers, S. P., Sintchak, J., Coll, J. T., Golec, J. M. C., Swenson, L., Wilson, K. P., and Charifson, P. S. (2000) *Chem. Biol.* **7**, 423–432
- Gorlich, D., and Mattaj, I. W. (1996) *Science* **271**, 1513–1518
- Yasuhara, N., Eguchi, Y., Tachibana, T., Imamoto, N., Yoneda, Y., and Tsujimoto, Y. (1997) *Genes Cells* **2**, 55–64

BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts

Masamichi Ono^a, Yoshiki Sawa^{a,*}, Masahiro Ryugo^a, Alexei N. Alechine^a, Shigeomi Shimizu^b, Rie Sugioka^b, Yoshihide Tsujimoto^b, Hikaru Matsuda^a

^aDepartment of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

^bDepartment of Post-Genomics and Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 18 May 2004; received in revised form 6 September 2004; accepted 9 September 2004

Abstract

Objective: To prevent apoptosis is thought to be promising for myocardial protection in cardiac surgery. Recently, we showed that BH4 domain of Bcl-xL is essential for the prevention of apoptosis, and that BH4 fused to HIV TAT protein (TAT-BH4) prevented apoptotic cell death. Then, we hypothesized TAT-BH4 may attenuate ischemia/reperfusion injury in rat hearts. **Methods:** The isolated rat hearts in the TAT-BH4 preconditioning group (BH4 group, $n=8$) or control group (C group, $n=8$) were subjected to warm ischemia (37 °C) for 30 min followed by 60 min of reperfusion using Langendorff perfusion system. **Results:** Left ventricular developed pressure and maximum dP/dt after reperfusion were significantly improved in the BH4 group than those in the C group ($P<0.01$). Recovery of mitochondrial respiration was significantly better in the BH4 group ($P<0.05$). Moreover, expression of caspase-3 and TUNEL-positive myocardium were decreased in the BH4 group than those in the C group. **Conclusions:** These results demonstrated that TAT-BH4 attenuates myocardial ischemia/reperfusion injury through preventing myocardial apoptosis. Thus, TAT-BH4 may be a novel therapeutic agent for myocardial protection in cardiac surgery.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Apoptosis; Cardiomyocytes; Ischemia/reperfusion injury; Heart surgery

1. Introduction

Recent advances in myocardial protection have improved the clinical results in open-heart surgery. However, severely critical cases associated with compromised heart, such as failing heart or post-ischemic conditions, still occur, and thus, further attempts to improve myocardial protection should be addressed.

Recently, a growing body of evidence have shown that apoptosis of myocardium is one of the major contributors to ischemic/reperfusion injury in experimental models [1-5] and even in humans after open-heart surgery [6,7]. Therefore, many attempts through molecular mechanism to attenuate apoptosis of myocardium in ischemia/reperfusion injury have been reported [8-15]. However, no pharmacological strategy has been reported to attenuate apoptosis in the heart. Moreover, strategy using gene transfection during ischemia has limitations because it takes few ours

to express proteins after reperfusion, which is not suitable for clinical application of myocardial protection against acute ischemic reperfusion injury.

We recently demonstrated that the biochemical role of the conserved N-terminal homology domain (BH4) of Bcl-xL is essential for the prevention of apoptosis, with respect to the regulation of mitochondrial membrane permeability and found that BH4 was required for Bcl-xL to prevent cytochrome c release. Using a newly developed TAT protein transduction system, which is the protein transduction domain of human immunodeficiency virus type 1 Tat protein (HIV TAT protein), we also showed that the BH4 domain fused to TAT protein (TAT-BH4), effectively prevented apoptotic cell death in vitro [16], and showed feasibility of protein transduction into cells in vivo. Chen et al. demonstrated TAT-BH4 attenuated myocardial infarction in vivo [17]. Therefore, it is expected that preconditioning of TAT-BH4 may attenuate ischemia/reperfusion injury of the myocardium during open heart surgery.

In this study, we investigated whether the preconditioning of TAT-BH4 may attenuate ischemia/reperfusion injury in isolated rat heart model as a pre-clinical trial.

* Corresponding author. Tel.: +81 6 6879 3151; fax: +81 6 6879 3163.
E-mail address: sawa@surg1.med.osaka-u.ac.jp (Y. Sawa).

2. Method

2.1. Test compounds

TAT-BH-4 protein and TAT mutant protein were provided by Shionogi Pharmacy Co., Ltd, Osaka, Japan. The proteins were dissolved in DMSO to the concentration of 5 µg/µl before use.

2.2. Pharmacological preconditioning and rat ischemia model

Sixteen Sprague-Dawley rats (300 g, male) were used for this study. Humane animal care complied with the 'Principle of Laboratory Animal Care' formulated by the National Society for Medical Research and the 'Guide for the Care and Use of Laboratory Animals' prepared by the Institute of Laboratory Animal Resource and published by the Institutes of Health (NIH Publication No. 86-23, revised 1985). The rats were divided into the control group (C group, $n=8$), and the TAT-BH-4 group (BH4 group, $n=8$). All rats were anesthetized by intra-peritoneal injection of sodium pentobarbital (50 mg/kg). Following 10 min of the injection and anticoagulation with heparin (200 USP units, intra-peritoneally), the hearts were quickly excised and perfused with modified Krebs-Henseleit buffer (120.0 mM NaCl, 4.5 mM KCl, 20.0 mM NaHCO₃, 1.2 mM KH₂PO₄, 1.2 mM MgCl₂, 2.5 mM CaCl₂, and 10.0 mM glucose: gassed with 95% O₂+5% CO₂ to obtain pH 7.4 at 37 °C) at the pressure equal to 1 m H₂O by means of a Langendorff apparatus. A thin-wall latex balloon was inserted into the left ventricle through the left atrium to monitor left ventricular pressure and to control left ventricular volume. After stabilization, heart rate (HR), left ventricular developed pressure (LVDP), maximum dP/dt (max dP/dt), and coronary flow (CF) were measured with LV diastolic pressure stabilized at 10 mmHg. Then, 100 µg (20 µl) of TAT-BH4 protein (BH4 group) or TAT mutant protein (C group), diluted by 5 ml of modified Krebs-Henseleit buffer, were administered through side port of apparatus at the speed of 1 ml/min. The hearts were then subjected to global ischemia at 37 °C for 30 min, followed by 60 min of reperfusion. The balloon was deflated during ischemia. The indices of cardiac function were continuously measured after reperfusion and analyzed using Polygraph System (Nihon Kouden, Japan). After 60 min of reperfusion, frozen sections of the hearts were made and stored at -80 °C for further assessment.

2.3. The recovery of mitochondrial respiration

Mitochondria were isolated from the hearts after reperfusion in 0.3 M mannitol/10 mM potassium HEPES, pH 7.4/0.2 mM EGTA, pH 7.4/0.1% fatty acid-free BSA by centrifugation at 2500×g for 10 min. The mitochondria were washed twice with this medium without EGTA to which 5 mM potassium phosphate was added and then suspended in it. Mitochondrial respiration was measured with an O₂ electrode, and the recovery of respiration was defined as the ratio of mitochondrial respiration in the hearts after reperfusion to the hearts before ischemia.

2.4. Western blotting analysis of active caspase-3

To evaluate the activation of apoptotic cascade after reperfusion, western blot analysis for detection of active caspase-3 was performed using the frozen section samples after 60 min of reperfusion. We used active caspase-3 rabbit polyclonal IgG antibody, and anti-rabbit secondary antibody conjugated to horseradish peroxidase and Phototope-HRP Western detection kit. The degree of the protein expression was semi-quantitatively evaluated with computed densitometry (Scion Image: Windows; Microsoft Corporation).

2.5. Histological analysis of apoptosis

The frozen section samples after 60 min of reperfusion were prepared for histological analysis. TUNEL staining was performed using Terminal Deoxynucleotidyl Transferase Mediated UTP-Biotin In Situ Nick-End Labeling (TUNEL Intergen Kit) according to the manufacturer's instruction. Quantitative assessment was calculated as a percentage of TUNEL-positive nuclei.

2.6. Statistical analysis

All data are expressed as mean ± standard error of the means (SEM). Scores were compared using an unpaired Student's *t* test. A *P* value of less than 0.05 was considered statistically significant.

3. Results

3.1. Recovery of cardiac function after global ischemia

To evaluate the efficacy of TAT-BH4 protein, we firstly analyzed cardiac function after global warm ischemia and reperfusion. The time course of percent recovery of LVDP after global ischemia (37 °C, 30 min) was shown in Fig. 1A. In comparison with the C group, a significant improvement of the percent recovery of LVDP was observed in the BH4 group at 10, 20, 30, 40, 50, and 60 min after reperfusion. The value after 60 min of reperfusion in the C group was 47 ± 4%, and was significantly improved to 72 ± 4% in the BH4 group ($P < 0.01$).

The time course of percent recovery of max dP/dt after global ischemia was shown in Fig. 1B. In comparison with the C group, a significant improvement of the index was observed in the BH4 group at 20, 30, 40, 50, and 60 min after reperfusion. The value after 60 min of reperfusion in the C group was 36 ± 9%, and was significantly improved to 71 ± 3% in the BH4 group ($P < 0.01$). CF after 60 min reperfusion was also significantly higher in the BH4 group compared with the C group (13.8 ± 0.9 vs. 8.9 ± 1.2 ml/min; $P < 0.01$) (Fig. 1C).

3.2. Mitochondrial function by the recovery of respiration

Consistently, mitochondrial function assessed by the recovery of respiration markedly increased (C; 30 ± 5, B; 77 ± 10%, $P < 0.05$) (Fig. 2).




Fig. 1. Cardiac function after reperfusion. The isolated hearts from the two groups were subjected to 30 min of normothermic global ischemia followed by 60 min of reperfusion. Better recovery of LVDP (A) and maximum dP/dt (B) after ischemia was shown in the BH4 group than in the C group. Data are expressed as percentage of basal value before ischemia. ** $P < 0.01$, * $P < 0.05$. The coronary flow after reperfusion (C): the coronary flow 60 min after reperfusion was measured. * $P < 0.05$. $n = 8$ in each group. All values are expressed as mean \pm SEM.




Fig. 2. The recovery of respiration: the recovery of mitochondrial respiration 60 min after reperfusion was measured. * $P < 0.05$. $n = 8$. All values are expressed as mean \pm SEM.




Fig. 3. Apoptosis of the myocardium after reperfusion. The myocardial expression of caspase-3 was significantly lower in the BH4 group than in the C group (A). The TUNEL-positive cardiomyocytes has detected in the control (B), but not in the BH4 group (C).

3.3. Evaluation of apoptosis by active caspase-3 expression and TUNEL staining

Then, we evaluated the apoptosis of the myocardium by Western blotting of active caspase-3 and TUNEL staining of the myocardium 60 min after reperfusion. The western blotting analysis for caspase-3 showed lower expression of active caspase-3 in the BH4 group compared with the C group (Fig. 3A). According to semi-quantitative analysis with computed densitometry, the BH4 group showed 1/3-1/4 less caspase-3 expression than the C group. The TUNEL staining of the heart section showed none of TUNEL-positive cells in the BH4 group (Fig. 3C), but significantly positive in the C group (Fig. 3B). The percent TUNEL-positive cells in the C group was $2.2 \pm 0.3\%$ of all cardiomyocytes, whereas TUNEL-positive cells could not be seen in BH4 group ($P < 0.01$).

4. Discussion

In the present report, we showed cardioprotective effect of TAT-BH4; a novel linkage of the protein transduction domain of HIV TAT to the functional domain of Bcl-xL. The recovery of cardiac function, mitochondrial respiration of the myocardium after ischemia/reperfusion was significantly better by TAT-BH4 administration. Moreover, TAT-BH4 attenuated caspase-3 expression and reduced apoptosis of cardiomyocytes.

Apoptosis is an actively regulated process of cellular self-destruction, thereby distinct from necrosis. It encloses mitochondrial changes with characteristic release of substances promoting apoptosis like cytochrome c. Downstream in the apoptotic program the caspase cascade such as caspase-3 is activated, followed by cytoskeletal alterations, chromatin condensation, and DNA fragmentation, culminating in cell death. Previous experimental studies have well shown that apoptosis of cardiomyocytes is induced from early stage of ischemia/reperfusion, playing an important role for the cardiac dysfunction [1-5]. Using isolated rat

heart model, Scarabelli et al. [4] demonstrated that apoptosis (caspase-3 and TUNEL-positive nuclei) is seen in the very early stages (5 min of reperfusion) of ischemia/reperfusion in both endothelial cells and cardiomyocytes. Previous clinical studies also demonstrated apoptosis is evident early after ischemia/reperfusion during open-heart surgery. Schmitt et al. [6] showed that cytochrome c release and TUNEL-positive myocytes were increased even at the time of weaning from extracorporeal circulation (40 min of reperfusion), and apoptotic index showed a negative correlation with left ventricular function during surgery. Wu et al. [7] demonstrated percent TUNEL-positive myocytes was significantly increased even just after cross-clamping release (10 min of reperfusion). These findings are consistent with our result of increased caspase-3 activities and TUNEL-positive myocytes 60 min after reperfusion.

There are many reports to attenuate ischemia/reperfusion injury through inhibiting apoptosis [8-15]. Several reports demonstrated the effects of gene transfer of anti-apoptotic gene [8-12]. Huang et al. [11] showed the effects of Bcl-xL gene transfer in rat model, but gene transfection needs a couple of days to gene expression, so this method is not suitable clinically for cardio-protection during open heart surgery. Other reports [13-15] showed the effects of anti-apoptotic protein administration such as caspase inhibitor [13], but this method needs frequent or continuous administration of relatively high dose of drugs during ischemia and reperfusion, which might induce deleterious side effects in other organs. Compared with the previous methods, TAT-BH4 administration before ischemia has some advantages over previous approach, because administration of essential domain for Bcl-xL by TAT system enables effective protein transduction into the target cells and potentiate immediately after reperfusion.

Our results showed that BH4 administration suppressed apoptotic cascade, resulting in improvement of cardiac function from early stage of reperfusion. Caspase-3 expression, an important molecule in the cellular suicide cascade, was minimal and no TUNEL-positive cells were seen in the BH4 group. The mechanism that BH4 inhibits apoptosis has already been demonstrated in our previous report [16]. BH4 of Bcl-xL is essential for inhibition of apoptosis with respect to the regulation of mitochondrial membrane permeability and is able to inhibit both voltage-dependent anion channel activity even in the presence of Bax and apoptotic mitochondrial membrane permeability loss. The mechanisms of this rapid effect for cardiac function by inhibiting apoptosis is remain to be addressed. Cheng et al. [18] reported that even such a small number of cells affected by apoptosis may have a significant impact on cardiac contractility, because single-cell death impinges upon the force-generating ability of neighboring cells that are still viable but stunned. Relatively few apoptotic cells may substantially impair side-to-side slippage of myocytes, resulting in a disproportionate and much more severe cardiac dysfunction. As a result, TAT-BH4 administration before ischemia inhibited almost completely apoptotic cascade during ischemia/reperfusion, contributing improvement of cardiac function from the early stage of reperfusion.

The HIV TAT protein: the amino-acid transduction domain of TAT contains a domain that facilitates protein transduction across cellular membranes. Although the exact mechanism of protein transduction across cellular membranes remains unknown, TAT-mediated protein transduction has been shown to occur even at 4°C and is receptor independent [19]. These characteristics of TAT protein are also thought to be promising for protein transduction during open heart surgery.

These well known mechanisms of TAT-BH4 preventing mitochondrial function and apoptosis characterizes the promising possibility for clinical appreciation of this agent in cardiac surgery. Our data have strongly supported the importance of further investigation for clinical appreciation of this agent in future.

In conclusion, we obtained evidence that TAT-BH4 attenuates myocardial ischemia/reperfusion injury via inhibition of apoptosis of the myocardium. Thus, TAT-BH4 may be a novel therapeutic strategy for the protection of post-operative cardiac dysfunction in cardiovascular surgery.

References

- [1] Gill C, Mestral R, Samali A. Losing heart: the role of apoptosis in heart disease—a novel therapeutic target? *Fed Am Soc Exp Biol J* 2002;16: 135-46.
- [2] Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R, Ullmann C, Lorenz-Meyer S, Schaper J. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. *J Mol Cell Cardiol* 2002;32:197-208.
- [3] Vazquez-Jimenez JF, Qing M, Hermanns B, Klosterhalfen B, Woltje M, Chakupurakal R, Schumacher K, Messmer BJ, von Bernuth G, Seghaye MC. Moderate hypothermia during cardiopulmonary bypass reduces myocardial cell damage and myocardial cell death related to cardiac surgery. *J Am Coll Cardiol* 2001;38:1216-23.
- [4] Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, Ferrari R, Knight R, Latchman D. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. *Circulation* 2001; 104:253-6.
- [5] Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. *J Clin Invest* 1994;94: 1621-8.
- [6] Schmitt JP, Schroder J, Schunkert H, Birnbaum DE, Aebert H. Role of apoptosis in myocardial stunning after open heart surgery. *Ann Thorac Surg* 2002;73:1229-35.
- [7] Wu ZK, Laurikka J, Saraste A, Kyto V, Pehkonen EJ, Savunen T, Tarkka MR. Cardiomyocyte apoptosis and ischemic preconditioning in open heart operations. *Ann Thorac Surg* 2003;76:528-34.
- [8] Sawa Y, Morishita R, Suzuki K, Kagasaki K, Kaneda Y, Maeda K, Kadoba K, Matsuda H. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFκB binding site: evidence for a role of NFκB in ischemia/reperfusion injury. *Circulation* 1997; 96(suppl):II-280-II-285.
- [9] Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. *Circulation* 2001;104(suppl 1): I-308-I-313.
- [10] Suzuki K, Murtuza B, Sammut IA, Latif N, Jayakumar J, Smolenski RT, Kaneda Y, Sawa Y, Matsuda H, Yacoub MH. Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. *Circulation* 2002;106(suppl):I-270-I-276.
- [11] Huang J, Ito Y, Morikawa M, Uchida H, Kobune M, Sasaki K, Abe T, Hamada H. Bcl-xL gene transfer protects the heart against ischemia/reperfusion injury. *Ann Thorac Surg* 2002;73:1229-35.

- [12] Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. *Ann J Physiol Heart Circ Physiol* 2003;285:H1506-H114.
- [13] Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. *Circulation* 1998;97:276-81.
- [14] Grunenfelder J, Miniati DN, Murata S, Falk V, Hoyt EG, Robbins RC. Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. *Circulation* 2001;104(suppl):I-202-I-206.
- [15] Maejima Y, Adachi S, Ito H, Nobori K, Tamamori-Adachi M, Isobe M. Nitric Oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulation cyclin A-associated kinase activity. *Cardiovasc Res* 2003;59:308-20.
- [16] Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. *Proc Natl Acad Sci USA* 2000;97:3100-5.
- [17] Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in ischemia/reperfusion injury. *J Biol Chem* 2002;277:29181-6.
- [18] Cheng W, Li B, Kajstura J, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch-induced programmed myocytes cell death. *J Clin Invest* 1995;96:2247-59.
- [19] Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb RA. TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective. *Circulation* 2002;106:735-9.



Two distinct Fas-activated signaling pathways revealed by an antitumor drug D609

Lilin Zhang¹, Shigeomi Shimizu¹ and Yoshihide Tsujimoto^{*1}

¹Laboratory of Molecular Genetics, Department of Post-Genomics and Diseases, Osaka University Medical School, Solution Oriented Research for Science and Technology (SORST), Japan Science and Technology Corporation, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

During the process of death receptor-mediated apoptosis, Bid is cleaved by activated caspase-8, and then cleaved Bid conveys apoptotic signals to the mitochondria by activating Bax/Bak. In the present study, we found that D609 (an antitumor drug with multiple activities) blocks Fas-induced apoptosis. D609 did not interfere with activation of caspase-8 and cleavage of Bid, whereas it blocked cytochrome *c* release from the mitochondria by inhibiting the activation of Bax and Bak. D609 had no protective effect against apoptosis of SKW6.4 cells, which are typical type I cells. Studies using permeabilized cells revealed that in addition to activation of caspase-8, Fas activated a distinct and D609-sensitive signaling pathway that transmitted signal(s) sensitizing the mitochondria to apoptotic stimuli, and that D609 itself promoted mitochondrial resistance to apoptotic stimuli.

Oncogene (2005) 24, 2954–2962. doi:10.1038/sj.onc.1208388
Published online 27 December 2004

Keywords: apoptosis; Bak; Bax; mitochondria; Fas

Introduction

Stimulation of death receptors such as Fas and TNF α triggers an apoptotic cascade, initially by recruiting a death receptor, adaptor protein Fas-associated death domain protein, and procaspase-8, to form the death-inducing signaling complex (DISC), after which procaspase-8 is cleaved and activated (Kischkel *et al.*, 1995; Boldin *et al.*, 1996; Wallach *et al.*, 1999). Two distinct Fas-induced apoptotic signaling pathways, the choice of which mainly depends on the extent of caspase-8 activated at the DISC, have been described (Scaffidi *et al.*, 1998). In type I cells, there is extensive activation of caspase-8, which is sufficient to activate downstream execution caspases such as caspase-3 or -7 that commit the cell to death. In type II cells, however, the DISC causes little activation of caspase-8; therefore, mito-

chondria-mediated amplification of apoptotic signals is necessary (Scaffidi *et al.*, 1998). In type II cells, activated caspase-8 cleaves and activates a BH3-only protein, Bid (Li *et al.*, 1998a; Luo *et al.*, 1998), which conveys apoptotic signals to the mitochondria by activating proapoptotic molecules Bax or Bak to induce mitochondrial release of cytochrome *c* (Desagher *et al.*, 1999; Eskes *et al.*, 2000; Wei *et al.*, 2000). After it is released into the cytoplasm, cytochrome *c* binds to apoptotic protease-activating factor 1 (Apaf1), which recruits and activates procaspase-9 to trigger activation of the caspase cascade and commit the cell to apoptotic death (Liu *et al.*, 1996; Li *et al.*, 1997).

In addition to the caspase-8/Bid signaling pathway, Fas has also been reported to stimulate other signaling pathways, leading to the activation of extracellular signal-regulated kinase (ERK) (Shinohara *et al.*, 2000; Desbarats *et al.*, 2003; Lambert *et al.*, 2003), c-Jun N-terminal kinase (JNK) (Yang *et al.*, 1997), tyrosine kinase (Eischen *et al.*, 1994), acidic sphingomyelinase (aSMase) (Cifone *et al.*, 1995), or phosphatidylcholine-specific phospholipase C (PC-PLC) (Cifone *et al.*, 1995). However, little is known about the role of these pathways in the regulation of apoptosis. Our previous study has revealed that Fas stimulates a caspase-8-independent signaling pathway, and although this pathway may not be able to induce directly apoptosis, it sensitizes the mitochondria to apoptotic stimuli by causing exposure of the N-terminus of Bak (Zhang *et al.*, 2004). These results suggested that in addition to the caspase-8/Bid pathway, Fas stimulates other signaling pathway(s) to regulate apoptosis, although the precise mechanisms are still to be determined.

The xanthogenate tricyclodecan-9-yl (D609) was originally developed as a selective antitumor drug (Amtmann and Sauer, 1987), and now is also known as an antioxidant (Zhou *et al.*, 2001) and inhibitor of PC-PLC and SMase (Schutze *et al.*, 1992; Wiegmann *et al.*, 1994; Amtmann, 1996). It has been reported that D609 impairs TNF-mediated cytotoxicity in murine fibrosarcoma L929 cells and WEHI164 cells, protects mice against TNF-, LPS-, or SEB-mediated lethal shock (Machleidt *et al.*, 1996), and inhibits glutamate-induced nerve cell death (Li *et al.*, 1998b). In the present study, we showed that D609 protected cells from Fas-induced apoptosis, not by interfering caspase-8/Bid activation

*Correspondence: Y Tsujimoto, Laboratory of Molecular Genetics, Department of Post-Genomics and Diseases, Osaka University Medical School, Rm B8 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; E-mail: tsujimoto@gene.med.osaka-u.ac.jp
Received 2 September 2004; revised 12 November 2004; accepted 19 November 2004; published online 27 December 2004

but by inhibiting the activation of Bak and Bax through blockage of caspase-8/Bid-independent apoptotic signaling and by increasing mitochondrial resistance to apoptotic signals.

Results

D609 inhibits Fas-induced apoptosis in HeLa and Jurkat cells

To develop a better understanding about Fas-induced apoptosis, we examined the influence of a variety of inhibitors on apoptosis induced by an agonistic anti-Fas antibody CH11 in HeLa cells. We found that D609 inhibited CH11-induced apoptosis in a dose-dependent manner, as assayed by Annexin-V staining (Figure 1a and b), nuclear morphology (Figure 1c), and activation of caspase-3 (Figure 1d). D609 also protected Jurkat cells from CH11-induced apoptosis (Figure 1e). In contrast, D609 did not have any protective effect against CH11-induced apoptosis of SKW6.4 cells, which

are typical type I cells (Figure 2a and b). These results suggested that D609 might prevent Fas-induced apoptosis by blocking a mitochondria-mediated apoptotic signaling pathway.

D609 inhibits activation of Bak/Bax and cytochrome c release

Next, we attempted to determine the mechanism by which D609 inhibited apoptosis. First, we examined whether D609 had any effect on an initial step in Fas-induced apoptosis, namely activation of caspase-8 and cleavage of Bid. D609 failed to inhibit the cleavage of procaspase-8 (Figure 3a, upper panel) in HeLa cells. Cleavage of Bid was slightly delayed (Figure 3a, middle panel), possibly due to inhibition of a caspase feedback pathway, since D609 blocked mitochondria-mediated amplification of apoptosis signaling (see below). To address this issue further, we investigated CH11-induced cleavage of Bid in the presence or absence of D609 in Bcl-2 overexpressing HeLa cells. After stimulation by CH11, cleavage of Bid showed the same kinetics




Figure 1 D609 prevents Fas-induced apoptosis. (a) HeLa cells were incubated with or without D609 at the indicated concentrations for 30 min, and then stimulated with or without 0.25 μ g/ml CH11 for the indicated times. Apoptotic cells were detected by Annexin-V staining. (b and c) HeLa cells were incubated with or without 0.25 μ g/ml CH11 in the presence or absence of 200 μ M D609 for the indicated times (b), or for 8 h (c). Apoptotic cells were detected by Annexin-V staining (b) or by staining with Hoechst 33342 (c). (d) HeLa cells were treated as in (b) for the indicated times. After lysis, cell extracts were subjected to Western blotting with an antibody to anti-active caspase-3. (e) Jurkat cells were treated with or without 0.25 μ g/ml CH11 in the presence or absence of 100 μ M z-VAD-fmk or 200 μ M D609 for the indicated times. Apoptotic cells were detected by Annexin-V staining




Figure 2 D609 is unable to prevent Fas-induced apoptosis in type I cells. (a) SKW6.4 cells were treated with or without 0.25 μ g/ml CH11 in the presence or absence of 200 μ M D609 for the indicated times. Apoptotic nuclei were detected by Hoechst 33342 staining. (b) SKW6.4 cells were treated as indicated and lysed, followed by Western blot analysis with antibodies to caspase-8, lamin B1, and active caspase-3

irrespective of the presence of D609 (Figure 3a, lower panel). These results are consistent with the finding that D609 could not inhibit CH11-induced apoptosis of SKW6.4 cell (Figure 2), suggesting that it prevented Fas-induced apoptosis without interfering with the activation of caspase-8/Bid.

To investigate whether D609 inhibited apoptosis upstream of the mitochondria, we examined a series of mitochondrial events occurring during apoptosis. D609 inhibited the release of cytochrome *c* from the mitochondria in CH11-stimulated HeLa cells (Figure 3b and c). Since Bak/Bax is thought to control the mitochondrial release of cytochrome *c* (Wei *et al.*, 2001), we investigated whether D609 had any effect on the activation of Bak or Bax. It has been reported that a conformational change and homo-oligomerization of Bax/Bak are closely associated with the activation of these proteins (Gross *et al.*, 1998; Hsu and Youle, 1998; Griffiths *et al.*, 1999; Antonsson *et al.*, 2000; Wei *et al.*, 2000; Cheng *et al.*, 2003); therefore, we examined the occurrence of these events in the presence or absence of D609 after CH11 stimulation. Employing specific antibodies that only recognized activated Bax/Bak that had undergone a conformational change, we found that D609 inhibited the CH11-induced conformational change of Bak and Bax (Figure 3b and d). D609 also inhibited translocation of Bax to the mitochondria (Figure 3c), and inhibited the oligomerization of Bak

and Bax in CH11-treated cells (Figure 3e and f). These results suggested that D609 inhibited apoptosis at the mitochondrial level or further upstream.

D609 confers mitochondrial resistance to Bid

Inhibition of Bax/Bak activation and cytochrome *c* release by D609 suggested that it inhibited apoptotic signaling pathways leading to the mitochondria and/or acted at the mitochondrial level. We examined both possibilities. First, to examine the latter possibility, we employed an *in vitro* assay using HeLa cells permeabilized by digitonin. To examine whether D609 inhibits apoptotic signaling at the mitochondria, HeLa cells were incubated with D609 for 30 min or 2 h, and then permeabilized, followed by incubating with various concentrations of recombinant human Bid (rBid) or with isotonic buffer as a negative control. Intriguingly, when HeLa cells were incubated with D609 for 2 h, rBid only induced little cytochrome *c* release in these cells (Figure 4), whereas incubation with D609 for a shorter period (30 min) could not inhibit rBid-induced cytochrome *c* release (Figure 5b). These results suggested that D609 could increase mitochondrial resistance to apoptotic stimulation.

D609 inhibits caspase-8-independent apoptotic signaling activated by Fas stimulation

To examine the possibility that D609 also inhibited apoptotic signals to the mitochondria, we also employed a permeabilized cell system. The lysate of cells treated with CH11 for 30 min was used. At 30 min, release of cytochrome *c* was not detected (data not shown). As shown in Figure 5a, the lysate derived from CH11-treated cells induced almost complete cytochrome *c* release from the mitochondria when was added to permeabilized cells. However, like lysate derived from untreated cells, the lysate derived from CH11/D609-treated cells did not induce cytochrome *c* release (Figure 5a). The addition of D609 to the lysates *in vitro* did not have any influence on cytochrome *c* release (Figure 5a, lower panel), suggesting that D609 did not have direct protective effect to the mitochondria. These results suggested that Fas stimulation not only activates the caspase-8/Bid pathway but also another signaling pathway to the mitochondria with a D609-sensitive step.

To confirm the existence of a Fas-activated caspase-8-independent signaling pathway to the mitochondria and to investigate whether this pathway could be inhibited by D609, cells were incubated with or without CH11 plus z-VAD-fmk in the presence or absence of D609, or D609 alone. After 30 min, the cells were permeabilized, incubated with different concentrations of rBid, and then cytochrome *c* release was detected by immunostaining. As shown in Figure 5b, particularly when rBid was added at a low concentration (0.01 μ g/ml), it induced very little release of cytochrome *c* in untreated cells, but it released cytochrome *c* from the mitochondria in CH11/z-VAD-fmk-treated cells, suggesting that CH11/z-VAD-fmk treatment sensitized the mitochon-




Figure 3 The protective effect of D609 occurs upstream of or at the mitochondria. (a) HeLa cells and HeLa cells overexpressing Bcl-2 (Hela-Bcl-2) were treated with or without 0.25 $\mu\text{g/ml}$ CH11 in the presence or absence of D609 (200 μM) for the indicated times, lysed, and subjected to Western blot analysis with antibodies for caspase-8 and Bid. (b) D609 inhibits CH11-induced release of cytochrome *c* and exposure of the N-terminus of Bak. HeLa cells were incubated with or without 0.25 $\mu\text{g/ml}$ CH11 in the presence or absence of D609 (200 μM) for 5 h, and then immunostained with antibodies to cytochrome *c* (upper panel) or Bak (Ab1) (lower panel). Scale bar = 20 μm . (c) D609 inhibits CH11-induced release of cytochrome *c* and mitochondrial translocation of Bax. HeLa cells were treated with or without CH11 (0.25 $\mu\text{g/ml}$) in the presence or absence of D609 (200 μM) or z-VAD-fmk (100 μM) for 5 h, and then fractionated into cytosolic (cytosol) and organellar (pellet) fractions, followed by Western blot analysis with antibodies to cytochrome *c* and Bax. (d) D609 inhibits CH11-induced exposure of the N-terminus of Bax. HeLa cells were treated as in (c) for 4 or 8 h. Cell extracts were immunoprecipitated with anti-Bax (6A7) monoclonal antibody that only recognized activated Bax, and then were subjected to Western blotting with a polyclonal anti-Bax antibody (N20). (e and f) D609 inhibits the oligomerization of Bak/Bax. Jurkat cells (e) and HeLa cells (f) were treated as indicated, harvested, and incubated with or without BMH for 30 min at room temperature. Oligomerization of Bak (e) and Bax (f) was detected by Western blotting. Asterisks denote dimers of respective proteins

dria to apoptotic signaling. When cells treated with CH11/z-VAD-fmk in the presence of D609 were permeabilized and incubated with the same concentration of rBid, the release of cytochrome *c* was markedly inhibited (Figure 5b). Incubation of cells with D609 alone for 30 min did not have any influence on rBid-

induced cytochrome *c* release (Figure 5b), indicating that incubation with D609 for a short time could not confer the mitochondria resistance to apoptotic signal. Since Fas-activated caspase-8/Bid pathway is completely inhibited by z-VAD-fmk but not by D609, all these results suggested that D609 could inhibit CH11-induced

caspace-8-independent apoptotic signaling to the mitochondria. Similar to the results revealed in Figure 5a, addition of D609 *in vitro* did not inhibit rBid-induced cytochrome *c* release (Figure 5b).

To further confirm the inhibition by D609 of CH11-induced caspace-8-independent apoptotic signaling to the mitochondria, caspace-8-deficient murine embryonic fibroblasts (caspace-8^{-/-} mouse embryonic fibroblasts (MEFs)) were employed. The cells were incubated with or without agonistic anti-mouse Fas antibody (Jo2), Jo2 plus D609, or D609 alone for 4 h, and then cytosols were prepared. Permeabilized HeLa cells were incubated with isotonic buffer or various cytosols for 10 min, and then




Figure 4 D609 promotes mitochondria resistance to Bid. HeLa cells were incubated with or without 200 µM D609 for 2 h, permeabilized by incubation with 20 µg/ml digitonin for 3 min at room temperature, and incubated with rBid for 10 min at 37°C. As a negative control, isotonic buffer was added instead of rBid. After washing three times, the cells were immunostained with anti-cytochrome *c* antibody. Note that cytochrome *c* release from the mitochondria caused loss of immunoreactivity to cytochrome *c* antibody due to leakage through the permeabilized plasmamembrane

stimulated with or without 0.01 µg/ml rBid. As shown in Figure 5c, any cytosol alone did not induce release of cytochrome *c*. Treatment with rBid induced the release of cytochrome *c* from the mitochondria in a small fraction of cells, and preincubation of permeabilized cells with the cytosol derived from control caspace-8^{-/-} MEFs only slightly enhanced rBid-induced release of







Figure 5 D609 inhibits CH11-induced caspace-8-independent apoptosis signaling. (a) Cytosol was prepared from HeLa cells incubated with or without 0.25 µg/ml CH11 in the presence or absence of 200 µM D609 for 30 min. Cytosols were added to permeabilized HeLa cells in the presence (lower panel) or absence (upper panel) of 20 µM D609 for 10 min at 37°C. As a negative control, isotonic buffer was added instead of cytosol. After washing three times, immunostaining was carried out with anti-cytochrome *c* antibody. Scale bar = 20 µm. (b) HeLa cells were incubated with (panels 2 and 5) or without (panel 1) 0.25 µg/ml CH11 plus 100 µM z-VAD-fmk, or with a combination of CH11, z-VAD-fmk, and 200 µM D609 (panel 3), or with D609 (200 µM) alone (panel 4) for 30 min, permeabilized, and then incubated with rBid (panels 1–4) or rBid plus 20 µM D609 (panel 5) for 5 min at 37°C. Isotonic buffer was added instead of rBid as a negative control. After washing three times, immunostaining was carried out with anti-cytochrome *c* antibody. Scale bar = 20 µm. Cells in which cytochrome *c* had been released from the mitochondria were counted. (c) Caspace-8^{-/-} MEFs were incubated with or without 0.5 µg/ml Jo2, Jo2 plus D609 (200 µM), or D609 (200 µM) alone for 4 h, and then the cytosols were prepared. Cytosols were added to permeabilized HeLa cells for 10 min at 37°C, followed by incubation with or without rBid (0.01 µg/ml) for 5 min. Isotonic buffer was added instead of rBid as a negative control. After washing three times, immunostaining was done with anti-cytochrome *c* antibody. Scale bar = 20 µm. Cells in which cytochrome *c* had been released from the mitochondria were counted

cytochrome *c*, whereas preincubation with the cytosol derived from Jo2-treated cells markedly promoted rBid-induced cytochrome *c* release (Figure 5c). This result is consistent with our previous finding (Zhang *et al.*, 2004). However, the cytosol derived from Jo2/D609-treated cells did not enhance rBid-induced cytochrome *c* release (Figure 5c). The cytosol derived from D609-treated cells did not affect rBid-induced cytochrome *c* release (Figure 5c), and, when was added to the cytosol derived from Jo2-treated cells, it could not inhibit Jo2 lysate-induced enhancement of rBid-induced cytochrome *c* release (data not shown). These results further indicated that Fas stimulated a caspase-8-independent apoptotic signaling to sensitize the mitochondria to apoptotic stimuli and this pathway could be prevented by D609.

D609 inhibits caspase-8-independent exposure of the N-terminus of Bak activated by Fas stimulation

Our previous study has revealed that Fas stimulation activates a caspase-8-independent signaling pathway that induces exposure of the N-terminus of Bak, and this change primes Bak for full activation and thus sensitizes the mitochondria to apoptotic stimuli (Zhang *et al.*, 2004). We examined whether D609 could inhibit this caspase-8-independent signaling pathway. As shown in Figure 6a, D609 completely inhibited CH11-induced caspase-8-independent exposure of the N-terminus of Bak. Since D609 might inhibit CH11-induced caspase-8-independent exposure of the N-terminus of Bak at the mitochondria level, we examined whether it inhibited caspase-8-independent signaling upstream of the mitochondria by employing a permeabilized cell system. As reported previously, cytosol derived from cells incubated with CH11 in the presence of z-VAD-fmk induced exposure of the N-terminus of Bak (Figure 6b) (Zhang *et al.*, 2004), while cytosol from cells incubated with CH11 in the presence of z-VAD-fmk plus D609 failed to induce this exposure (Figure 6b). The addition of D609 to the lysate did not inhibit exposure of the N-terminus of Bak (data not shown). These results further confirmed that other signaling pathway(s) originated from the death receptor to participate in the regulation of apoptosis in addition to caspase-8/Bid pathway.

Discussion

In type II cells, mitochondria-mediated apoptotic signaling plays an essential role in Fas-induced apoptosis, since such apoptosis is completely blocked when mitochondrial permeabilization is prevented either by overexpression of Bcl-2/Bcl-x_L (Scaffidi *et al.*, 1998) or deficiency of Bax/Bak (Wei *et al.*, 2001), while apoptosis is severely delayed when Bid, which transmits apoptotic signals to the mitochondria, is eliminated by genetic alteration (Yin *et al.*, 1999). Fas stimulation does not only activate the caspase-8/Bid pathway but also other signaling pathway(s) such as ERK (Shinohara *et al.*, 2000; Desbarats *et al.*, 2003), PC-PLC (Cifone *et al.*, 1995), JNK (Yang *et al.*, 1997), and aSMase (Cifone




Figure 6 D609 inhibits CH11-induced caspase-8-independent exposure of the N-terminus of Bak. (a) HeLa cells were incubated for 2 h without or with 0.25 μ g/ml CH11 in the presence or absence of 100 μ M z-VAD-fmk, or with a combination of CH11, z-VAD-fmk, and 200 μ M D609, and then were immunostained with anti-Bak (Ab1) antibody. (b) Digitonin-permeabilized HeLa cells were incubated for 10 min with cytosol derived from HeLa cells treated as in (a), followed by immunostaining with an anti-Bak monoclonal antibody (Ab1). Isotonic buffer was added instead of cytosol as the negative control. Scale bar = 20 μ m

et al., 1995). To date, whether these pathways play any roles in the regulation of apoptosis is still unclear. Here, we showed that D609 prevents Fas-induced apoptosis not by interfering caspase-8/Bid activation but, at least partly, by inhibiting Fas-mediated caspase-8-independent apoptotic signaling to the mitochondria (Figure 7). This result suggested that in addition to caspase-8/Bid pathway, Fas stimulation also activates other signaling to regulate apoptosis. It is currently unclear how D609 inhibited this signaling pathway, since D609 has been reported to inhibit PC-PLC and SMase activity (Schutze *et al.*, 1992; Wiegmann *et al.*, 1994; Amtmann, 1996; Machleidt *et al.*, 1996), and is also known as an antioxidant (Zhou *et al.*, 2001). Although the target of D609 has not been identified, D609 has enabled us to identify a novel apoptotic signaling pathway that is




Figure 7 Two independent signaling pathways activated by Fas stimulation in type II cells. Fas activates two distinct signaling pathways to the mitochondria to regulate apoptosis: the caspase-8/Bid-dependent and -independent pathways. Although this caspase-8-independent pathway might not induce apoptosis directly, it sensitizes the mitochondria to apoptotic stimulation. D609 prevents Fas-induced apoptosis by inhibiting the caspase-8-independent signaling pathway to the mitochondria as well as protecting the mitochondria

activated by Fas and is independent of caspase-8/Bid. Our previous study also revealed that Fas stimulates a caspase-8-independent signaling pathway, which is staurosporine-inhibitable, and, although this pathway may not be able to induce directly apoptosis, it sensitizes the mitochondria to apoptotic stimuli by causing exposure of the N-terminus of Bak (Zhang *et al.*, 2004). We found that D609 completely inhibited the CH11-induced caspase-8-independent signaling pathway leading to the exposure of Bak N-terminus. These findings also suggested that in addition to the caspase-8/Bid pathway, Fas stimulates other signaling pathway(s) to regulate apoptosis.

We also showed that D609 decreased susceptibility of the mitochondria to apoptotic signal (Figure 7). Consistently, D609 inhibited not only Fas-induced apoptosis but also etoposide-induced apoptosis (unpublished data). D609 may decrease mitochondrial susceptibility by inhibiting the exposure of N-terminus of Bak, although another possibility exists because D609 also inhibited the activation of Bax. It has been reported that dynamic changes of mitochondrial membrane lipids occur during Fas- and radiation-induced apoptosis (Matsko *et al.*, 2001). In the present study, we found that Fas stimulation increased PC-PLC activity, and D609, but not caspase inhibitor z-VAD-fmk, inhibited this increased activity (data not shown). PC-PLC is a phospholipase; the hydrolysis of lipid and/or the reaction products could affect lipid homeostasis in the mitochondria. Since Bak is localized on the outer mitochondrial membrane, it is conceivable that changes

of the membrane lipids could affect the conformation of Bak. To exert proapoptotic activity, Bax undergoes translocation and is inserted into the mitochondrial membrane, where it oligomerizes to contribute to the formation of a protein-conducting pore (Wolter *et al.*, 1997; Antonsson *et al.*, 2000, 2001; Eskes *et al.*, 2000). Recent studies have revealed that Bax-induced permeabilization of liposomes is dependent on cardiolipin, which is a specific mitochondrial membrane lipid (Erand *et al.*, 2002; Kuwana *et al.*, 2002). In the absence of liposomes, tBid failed to induce the conformational change and oligomerization of Bax (Yethon *et al.*, 2003), suggesting that an appropriate lipid environment is required for Bax to undergo translocation and insertion into the mitochondrial membrane. It is possible that mitochondrial membrane lipids are altered by PC-PLC or other molecule to facilitate the conformational change of Bax, as well as its mitochondrial translocation and membrane insertion. It is currently unclear whether the protective effect of D609 is exerted via inhibition of PC-PLC, and also whether PC-PLC really plays an important role in the regulation of Fas-induced apoptosis, since PC-PLC itself has not been identified in eukaryote. This will be unveiled when eukaryotic PC-PLC is cloned or when other target(s) of D609 are found. Alternatively, death stimulation induces generation of reactive oxygen species (ROS), and ROS influences lipid homeostasis in the mitochondria, therefore promoting activation of Bak or Bax. D609 has been reported as a potent antioxidant, and this effect may interpret that D609 inhibited etoposide-induced apoptosis at the mitochondrial level (unpublished data).

It has been reported that aSMase/ceramide plays an important role in Fas-induced apoptosis and that D609 inhibits aSMase activation (Schutze *et al.*, 1992; Boesende Cock *et al.*, 1999; Lin *et al.*, 2000; Paris *et al.*, 2001). Therefore, it is possible that the inhibition of Fas-induced apoptosis by D609 is due to inhibition of aSMase/ceramide. However, this is unlikely, because blocking the production of ceramide with an aSMase inhibitor (imipramine) or an inhibitor of ceramide synthase (fumonisins B1) did not have any protective effect against Fas-induced apoptosis (data not shown), suggesting that aSMase may not participate in this form of apoptosis and that protective effect of D609 is not mediated via inhibition of aSMase in these cells. Identification of true targets of D609 would develop a better understanding about apoptosis regulation.

Materials and methods

Antibodies and Reagents

Anti-Bak (Ab1) monoclonal and polyclonal antibodies were purchased from Oncogene Research Products (Boston, MA, USA) and Upstate Biotechnology (Lake Placid, NY, USA), respectively. Anti-Bax (N20) and anti-Bid polyclonal antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and R&D System (Minneapolis, MN, USA), respectively. Anti-cytochrome *c* (6H2 and 7H8), anti-Bax (6A7) and anti-mouse Fas (Jo2) monoclonal antibodies were

from Pharmingen (San Diego, CA, USA). Anti-human Fas (CH11), anti-caspase-3, and anti-caspase-8 monoclonal antibodies were obtained from MBL (Nagoya, Japan), while anti-lamin B1 and anti-active caspase-3 antibodies were purchased from Zymed Laboratories (San Francisco, CA, USA) and Promega (Madison, WI, USA), respectively. All of the secondary antibodies were purchased from Molecular Probes (Eugene, OR, USA).

The crosslinker bismaleimido-hexane (BMH) came from Pierce Biotechnology (Rockford, IL, USA). D609 was purchased from Calbiochem (San Diego, CA, USA), while the other chemicals were obtained from Sigma (Saint Louis, MS, USA). rBid was prepared as described previously (Shimizu and Tsujimoto, 2000).

Cell culture

The human HeLa cell line, human Jurkat T-leukemic cell line, and human SKW6.4. B lymphoblastoid cell line were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). MEFs derived from caspase-8-deficient mice were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS.

Immunofluorescence staining

Cells were fixed in 4% paraformaldehyde for 30 min, and then permeabilized with 0.1% Triton X-100 for 15 min at room temperature. After incubation with 2% FBS in phosphate-buffered saline (PBS) for 1 h, the cells were incubated with anti-Bax (Ab1) (1:500) or anti-cytochrome *c* (1:500) for 1 h. After washing three times with PBS, the cells were incubated with the secondary antibody (Alexa 488-conjugated anti-mouse IgG) for 1 h. Then fluorescence was detected under a confocal microscope (Zeiss, LSM510). In all immunostaining experiments, normal mouse IgG was added instead of the primary antibody (IgG) as a negative control.

Immunoprecipitation

HeLa cells were treated, harvested, and lysed with HNC buffer (25 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM dithiothreitol (DTT), 2% CHAPS). The extracts were precleared, incubated with a monoclonal anti-Bax antibody (6A7) (1 μ g) or normal mouse IgG (1 μ g) for 3 h at 4°C, and then incubated with protein A beads for further 3 h. After washing five times with HNC buffer, the beads were suspended in sample buffer and then were subjected to Western blotting with a polyclonal anti-Bax antibody (N20).

Analysis of cell death

Cell viability was assessed by staining with Annexin-V or Hoechst 33342. Briefly, cells were stained with Cy3-conjugated Annexin-V or 1 μ M Hoechst 33342 for 5 min at room

temperature, and then analysed using a flow cytometer or examined under a fluorescence microscope (Olympus, BX50). Cells with condensed and fragmented nuclei were classified as apoptotic cells and were counted in four randomly chosen fields.

Crosslinking

Cells were harvested, incubated with 1 mM BMH for 30 min at room temperature, and then incubated with 1 mM DTT for 15 min to quench the cross-linker. Next, the cells were solubilized in sample buffer and analysed by Western blotting. As a control, the same concentration of Me₂SO (DMSO) was added instead of BMH.

Permeabilization of cells

HeLa cells were cultured in 10-well glass slides. After washing twice with isotonic buffer (20 mM HEPES-KOH (pH 7.4), 1.5 mM MgCl₂, 10 mM KCl, 250 mM sucrose), the cells were incubated with isotonic buffer containing 20 μ g/ml digitonin for 3 min at room temperature. After washing three times with isotonic buffer, the cells were incubated with cytosol, or rBid at 37°C. After washing another three times with isotonic buffer, the cells were subjected to immunostaining.

Preparation of cytosol

After washing three times with isotonic buffer, cells were suspended in the same volume of isotonic buffer supplemented with protease inhibitors, and then homogenized using a Dounce homogenizer. After centrifugation at 100 000 g for 1 h, the supernatant was obtained and used as the cytosol.

Subcellular fractionation

Cells were fractionated as described previously (Nomura *et al.*, 1999). Briefly, the cells were harvested, washed three times with isotonic buffer, and then incubated with 30 μ g/ml digitonin in isotonic buffer for 5 min at 37°C. After centrifugation at 3000 r.p.m. for 3 min, aliquots of the supernatant (cytosolic fraction) and the pellet (containing the mitochondria) were analysed by Western blotting with anti-cytochrome *c* and anti-Bax antibodies.

Acknowledgements

We thank Drs K Sakamaki and S Yonehara for kindly providing caspase-8-deficient MEFs. This study was supported in part by a grant for Scientific Research on Priority Areas, a grant for Center of Excellence Research, a grant for the 21st century COE program, and a grant for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

References

- Amtmann E. (1996). *Drugs Exp. Clin. Res.*, **22**, 287–294.
Amtmann E and Sauer G. (1987). *Cancer Lett.*, **35**, 237–244.
Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC. (2000). *Biochem. J.*, **345** (Part 2), 271–278.
Antonsson B, Montessuit S, Sanchez B and Martinou JC. (2001). *J. Biol. Chem.*, **276**, 11615–11623.
Boesen-de Cock JG, Tepper AD, de Vries E, van Blitterswijk WJ and Borst J. (1999). *J. Biol. Chem.*, **274**, 14255–14261.
Boldin MP, Goncharov TM, Goltsev YV and Wallach D. (1996). *Cell*, **85**, 803–815.
Cheng EH, Sheiko TV, Fisher JK, Craigen WJ and Korsmeyer SJ. (2003). *Science*, **301**, 513–517.
Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G and Testi R. (1995). *EMBO J.*, **14**, 5859–5868.
Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou JC. (1999). *J. Cell Biol.*, **144**, 891–901.

- Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palermo JS and Newell MK. (2003). *Nat. Cell Biol.*, **5**, 118–125.
- Eischen CM, Dick CJ and Leibson PJ. (1994). *J. Immunol.*, **153**, 1947–1954.
- Epand RF, Martinou JC, Fornallaz-Mulhauser M, Hughes DW and Epand RM. (2002). *J. Biol. Chem.*, **277**, 32632–32639.
- Eskes R, Desagher S, Antonsson B and Martinou JC. (2000). *Mol. Cell. Biol.*, **20**, 929–935.
- Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM, Dive C and Hickman JA. (1999). *J. Cell Biol.*, **144**, 903–914.
- Gross A, Jockel J, Wei MC and Korsmeyer SJ. (1998). *EMBO J.*, **17**, 3878–3885.
- Hsu YT and Youle RJ. (1998). *J. Biol. Chem.*, **273**, 10777–10783.
- Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Kramer PH and Peter ME. (1995). *EMBO J.*, **14**, 5579–5588.
- Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneider R, Green DR and Newmeyer DD. (2002). *Cell*, **111**, 331–342.
- Lambert C, Landau AM and Desbarats J. (2003). *Apoptosis*, **8**, 551–562.
- Li H, Zhu H, Xu CJ and Yuan J. (1998a). *Cell*, **94**, 491–501.
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X. (1997). *Cell*, **91**, 479–489.
- Li Y, Maher P and Schubert D. (1998b). *Proc. Natl. Acad. Sci. USA*, **95**, 7748–7753.
- Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, Paris F, Fuks Z, Schuchman EH, Kolesnick RN and Green DR. (2000). *J. Biol. Chem.*, **275**, 8657–8663.
- Liu X, Kim CN, Yang J, Jemerson R and Wang X. (1996). *Cell*, **86**, 147–157.
- Luo X, Budihardjo I, Zou H, Slaughter C and Wang X. (1998). *Cell*, **94**, 481–490.
- Machleidt T, Kramer B, Adam D, Neumann B, Schutze S, Wiegmann K and Kronke M. (1996). *J. Exp. Med.*, **184**, 725–733.
- Matsko CM, Hunter OC, Rabinowich H, Lotze MT and Amoscato AA. (2001). *Biochem. Biophys. Res. Commun.*, **287**, 1112–1120.
- Nomura M, Shimizu S, Ito T, Narita M, Matsuda H and Tsujimoto Y. (1999). *Cancer Res.*, **59**, 5542–5548.
- Paris F, Grassme H, Cremesti A, Zager J, Fong Y, Haimovitz-Friedman A, Fuks Z, Gulbins E and Kolesnick R. (2001). *J. Biol. Chem.*, **276**, 8297–8305.
- Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Kramer PH and Peter ME. (1998). *EMBO J.*, **17**, 1675–1687.
- Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K and Kronke M. (1992). *Cell*, **71**, 765–776.
- Shimizu S and Tsujimoto Y. (2000). *Proc. Natl. Acad. Sci. USA*, **97**, 577–582.
- Shinohara H, Yagita H, Ikawa Y and Oyaizu N. (2000). *Cancer Res.*, **60**, 1766–1772.
- Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP. (1999). *Annu. Rev. Immunol.*, **17**, 331–367.
- Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB and Korsmeyer SJ. (2000). *Genes Dev.*, **14**, 2060–2071.
- Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ. (2001). *Science*, **292**, 727–730.
- Wiegmann K, Schutze S, Machleidt T, Witte D and Kronke M. (1994). *Cell*, **78**, 1005–1015.
- Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ. (1997). *J. Cell Biol.*, **139**, 1281–1292.
- Yang X, Khosravi-Far R, Chang HY and Baltimore D. (1997). *Cell*, **89**, 1067–1076.
- Yethon JA, Epand RF, Leber B, Epand RM and Andrews DW. (2003). *J. Biol. Chem.*, **278**, 48935–48941.
- Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA and Korsmeyer SJ. (1999). *Nature*, **400**, 886–891.
- Zhang L, Shimizu S, Sakamaki K, Yonehara S and Tsujimoto Y. (2004). *J. Biol. Chem.*, **279**, 33865–33874.
- Zhou D, Lauderback CM, Yu T, Brown SA, Butterfield DA and Thompson JS. (2001). *J. Pharmacol. Exp. Ther.*, **298**, 103–109.